ライフサイエンスコーパス: fumarate

1 lafenamide and 292 with tenofovir disoproxil fumarate).

2 288 patients receiving tenofovir disoproxil fumarate).

3 ide and 867 given E/C/F/tenofovir disoproxil fumarate).

4 avirenz, emtricitabine, tenofovir disoproxil fumarate).

5 clude emtricitabine and tenofovir disoproxil fumarate).

6 ine, emtricitabine, and tenofovir disoproxil fumarate.

7 enz, emtricitabine, and tenofovir disoproxil fumarate.

8 with emtricitabine and tenofovir disoproxil fumarate.

9 tenofovir alafenamide to tenofovir disproxil fumarate.

10 ining on one containing tenofovir disoproxil fumarate.

11 afenamide compared with tenofovir disoproxil fumarate.

12 cer and the multiple sclerosis drug dimethyl fumarate.

13 p occurs when the chiral toluenes react with fumarate.

14 dratase-proficient cells with cell-permeable fumarate.

15 and 2.16 (95% CI, 1.88-2.48) for quetiapine fumarate.

16 ne safety compared with tenofovir disoproxil fumarate.

17 se of emtricitabine and tenofovir disoproxil fumarate.

18 UAC1 accumulated higher levels of malate and fumarate.

19 emical approach to detect the oncometabolite fumarate.

20 from emtricitabine with tenofovir disoproxil fumarate.

21 efavirenz/emtricitabine/tenofovir disoproxil fumarate.

22 range of hydrocarbons through attachment to fumarate.

23 enofovir alafenamide to tenofovir disoproxil fumarate.

24 the accumulation of the TCA cycle metabolite fumarate.

25 tor, emtricitabine, and tenofovir disoproxil fumarate.

26 95% CI 0.00 to 0.02] vs tenofovir disoproxil fumarate 0.02 mg/dL [0.00 to 0.04], adjusted percentage

27 than those given E/C/F/tenofovir disoproxil fumarate (0.08 vs 0.12 mg/dL; p<0.0001), significantly l

28 de 40 [14%] patients vs tenofovir disoproxil fumarate 14 [10%] patients), nasopharyngitis (30 [11%] v

29 daily and emtricitabine/tenofovir disoproxil fumarate (200/300 mg) once daily.

30 receive daily combined tenofovir disoproxil fumarate (245 mg) and emtricitabine (200 mg) either imme

31 nce a day or to receive tenofovir disoproxil fumarate 300 mg once a day; each allocation was given wi

32 ir alafenamide 25 mg or tenofovir disoproxil fumarate 300 mg, each with matching placebo.

33 standard of care (SOC) (tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, and ATV/RTV 300 m

34 combination tablets of tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) and advised

35 icitabine (200 mg), and tenofovir disoproxil fumarate (300 mg), with matching placebo, once daily for

36 icitabine (200 mg), and tenofovir disoproxil fumarate (300 mg), with matching placebo.

37 r placebo for 90 days followed by clemastine fumarate (5.36 mg orally twice daily) for 60 days (group

38 umber generator to receive either clemastine fumarate (5.36 mg orally twice daily) for 90 days follow

39 tasone dipropionate (100 mug) and formoterol fumarate (6 mug) in two actuations twice daily.

40 etal-organic framework {MOF-801, [Zr6O4(OH)4(fumarate)6]} that captures water from the atmosphere at

41 Fumarate, a small molecule metabolite that accumulates i

42 ecific Fh1 deletion (resulting in endogenous fumarate accumulation and a genetic TCA cycle block refl

43 Although it is known that fumarate accumulation can alter cellular signaling, if a

44 Here we show that fumarate accumulation confers a chronic proliferative si

45 ts imply that loss of fumarate hydratase and fumarate accumulation contribute to the aggressive featu

46 We conclude that fumarate accumulation plays an essential role in low tem

47 However, the link between fumarate accumulation, epigenetic changes, and tumorigen

48 marate hydratase (FH), which regulates urine fumarate accumulation, was reduced in the diabetic kidne

49 ypes, indicating the causal role of cellular fumarate accumulation.

50 d residues 21-41 in the membrane in both the fumarate-activated (ON) and inactive (OFF) states.

51 , implying that paraffins are activated via 'fumarate addition'.

52 nal year of exposure to tenofovir disoproxil fumarate (adjusted incidence rate ratio 1.14 [95% CI 1.1

53 ynthase (BSS), in two oligomeric states with fumarate alone or with both substrates.

54 Dimethyl fumarate also significantly decreased serum MDA and rena

55 ethyl group of toluene is positioned between fumarate and a cysteine that forms a thiyl radical durin

56 loadditions of cyclopentadiene with dimethyl fumarate and dimethyl 1,1-ethylenedicarboxylate.

57 Daily, oral use of tenofovir disoproxil fumarate and emtricitabine (TDF-FTC) for preexposure pro

58 prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine for the prevention of HIV inf

59 navir plus coformulated tenofovir disoproxil fumarate and emtricitabine once a day (atazanavir group)

60 r and 2 nucleos(t)ides (tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine) a

61 twice daily, each with tenofovir disoproxil fumarate and emtricitabine orally once daily, for up to

62 the number of doses of tenofovir disoproxil fumarate and emtricitabine taken per week, as estimated

63 on of succinicGSH, a covalent adduct between fumarate and glutathione.

64 LND inhibits the formation of fumarate and malate and suppresses succinate-induced res

65 The iron-sulfur cluster containing protein Fumarate and Nitrate Reduction (FNR) is the master regul

66 brane resulting in rapid efflux of succinate/fumarate and other dicarboxylates capable of competitive

67 operties can be tuned to enable detection of fumarate and other dipolarophile metabolites.

68 powder (MNP) containing a mixture of ferrous fumarate and sodium iron EDTA (FeFum+NaFeEDTA) in Kenyan

69 Fumarate and succinate also down-regulated global 5-hmC

70 R, FrdABCD) catalyzes the interconversion of fumarate and succinate at a covalently attached FAD with

71 Fumarate and succinate, which can accumulate to millimol

72 lar efficacy to that of tenofovir disoproxil fumarate and was associated with a smaller decrease in b

73 288 patients receiving tenofovir disoproxil fumarate) and AST (20 [3%] of 577 patients receiving ten

74 lizumab, fingolimod, teriflunomide, dimethyl fumarate, and alemtuzumab-with regard to their mechanism

75 on of beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (BDP/FF/GB) in COPD

76 afine beclometasone dipropionate, formoterol fumarate, and glycopyrronium bromide (BDP/FF/GB; fixed t

77 non-inferior to that of tenofovir disoproxil fumarate, and had improved bone and renal effects.

78 ide was non-inferior to tenofovir disoproxil fumarate, and had improved bone and renal effects.

79 dard regimen containing tenofovir disoproxil fumarate, and might be a treatment option for patients a

80 Succinate, fumarate, and PBS have no effect on cell viability, rega

81 y) experiments in the presence of succinate, fumarate, and phosphate-buffered saline (PBS) in differe

82 chromatography-mass spectrometry, identifies fumarate as a key component of the cold response in this

83 nalyse the efficacy and safety of clemastine fumarate as a treatment for patients with multiple scler

84 during bacterial anaerobic respiration with fumarate as the terminal electron acceptor.

85 s more efficiently than tenofovir disoproxil fumarate at a lower dose, thereby reducing systemic expo

86 with emtricitabine plus tenofovir disoproxil fumarate at a research centre in Cape Town, South Africa

87 ative individuals using tenofovir disoproxil fumarate-based pre-exposure prophylaxis for the preventi

88 th beclometasone dipropionate and formoterol fumarate (BDP/FF) treatment.

89 me that catalyzes the addition of toluene to fumarate, benzylsuccinate synthase (BSS), in two oligome

90 Mechanistically, fumarate binds to and activates a reactive oxygen specie

91 igodendrocyte plasma membrane and clemastine fumarate can stimulate differentiation of oligodendrocyt

92 the other hand, downregulating PCK2 hindered fumarate carbon flows in TCA cycle, leading to attenuate

93 Here, we show that the accumulation of fumarate caused by the inactivation of FH leads to oxida

94 tat, emtricitabine, and tenofovir disoproxil fumarate (combined ART).

95 tat, emtricitabine, and tenofovir disoproxil fumarate compared with a boosted protease inhibitor regi

96 3, Mia40, and Erv1, the addition of Osm1 and fumarate completes the disulfide exchange pathway that r

97 ion can alter cellular signaling, if and how fumarate confers a growth advantage remain unclear.

98 7.6%) patients received tenofovir disoproxil fumarate-containing ART, in line with nationally recomme

99 ng one of four previous tenofovir disoproxil fumarate-containing regimens (tenofovir disoproxil fumar

100 were taking one of four tenofovir disoproxil fumarate-containing regimens for at least 96 weeks befor

101 reconstitution assays support that the Osm1/fumarate couple accepts electrons with similar efficienc

102 Specifically, fumarate covalently modifies cysteine residues on iron r

103 .e. acrylate (D1), methacrylate (D2), methyl fumarate (D3) and ethyl fumarate (D4).

104 crylate (D2), methyl fumarate (D3) and ethyl fumarate (D4).

105 iron supplementation (60 mg iron as ferrous fumarate daily).

106 omized 1:1:1 to receive tenofovir-disoproxil fumarate (DF) plus emtricitabine, and either cobicistat-

107 one patient assigned to tenofovir disoproxil fumarate did not receive the treatment.

108 140 patients receiving tenofovir disoproxil fumarate (difference 1.8% [95% CI -3.6 to 7.2]; p=0.47),

109 Dimethyl fumarate (DMF) (BG-12, Tecfidera) is a fumaric acid este

110 We show here that dimethyl fumarate (DMF) dose-dependently induces mitochondrial bi

111 tudy was to explore the efficacy of dimethyl fumarate (DMF) in preventing disease reactivation after

112 Dimethyl Fumarate (DMF) is an FDA approved anti-oxidative and ant

113 Dimethyl fumarate (DMF) is indicated for the treatment of relapsi

114 vestigate the protective effects of dimethyl fumarate (DMF) on CsA-induced nephrotoxicity by enhancin

115 We investigated the effects of dimethyl fumarate (DMF) on CTCL cells in vitro and in vivo.

116 Dimethyl fumarate (DMF) possesses anti-inflammatory properties an

117 ress this need, we examined whether dimethyl fumarate (DMF), an anti-inflammatory drug already in cli

118 s, including sulforaphane (SFN) and dimethyl fumarate (DMF), are unable to induce a similar response.

119 Fumaric acid esters, including dimethyl fumarate (DMF, Tecfidera; Biogen, Cambridge, MA), have s

120 Dimethyl fumarate (DMF; trade name Tecfidera) is an oral formulat

121 alafenamide) or 300 mg tenofovir disoproxil fumarate (E/C/F/tenofovir disoproxil fumarate) with matc

122 efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF).

123 osed from conception to tenofovir disoproxil fumarate, emtricitabine, and efavirenz (TDF-FTC-EFV) (90

124 ventions worldwide, yet tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for PrEP is only licens

125 s randomized equally to tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) plus atazanavir/ritonav

126 lly suppressed on tenofovir (TFV) disoproxil fumarate/emtricitabine and ritonavir-boosted atazanavir

127 Daily tenofovir disoproxil fumarate/emtricitabine is recommended for use as preexpo

128 e kinase (BTK) inhibitor Ibrutinib bearing a fumarate ester electrophile is vulnerable to enzymatic m

129 obicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF) with that of efavirenz/emtricit

130 (4%) patients receiving tenofovir disoproxil fumarate experienced serious adverse events, none of whi

131 daily emtricitabine and tenofovir disoproxil fumarate for 8 months presented with fever, urinary trac

132 enz, emtricitabine, and tenofovir disoproxil fumarate for at least 6 months before enrolment and had

133 ine, emtricitabine, and tenofovir disoproxil fumarate for at least 6 months before enrolment and had

134 (TFV) and oral emtricitabine/TFV disoproxil fumarate (FTC/TDF).

135 g., lactic acid, dihydroxyacetone, glycerol, fumarate) gives rise to almost limitless biomaterial str

136 mely chlorophyll a, chlorophyll b, fructose, fumarate, glucose, glutamate, malate, nitrate, starch, s

137 carboxylic acid cycle intermediates (malate, fumarate), glutamate, fatty acid acylcarnitines, tryptop

138 4 (93%) assigned to the tenofovir disoproxil fumarate group (adjusted difference 4.1%, 95% CI 1.6-6.7

139 d with 307 (93%) in the tenofovir disoproxil fumarate group (difference 1.3%, 95% CI -2.5 to 5.1), sh

140 h 88 (89%) of 99 in the tenofovir disoproxil fumarate group (modified intention-to-treat population).

141 ent; one patient in the tenofovir disoproxil fumarate group died, but this was not deemed to be relat

142 ) and three (1%) in the tenofovir disoproxil fumarate group discontinued due to adverse events.

143 of 292 patients in the tenofovir disoproxil fumarate group had grade 3 or 4 laboratory abnormalities

144 topenia) and two in the tenofovir disoproxil fumarate group had study drug-related serious adverse ev

145 of 867 patients in the tenofovir disoproxil fumarate group having plasma HIV-1 RNA less than 50 copi

146 te-containing regimens (tenofovir disoproxil fumarate group) for 96 weeks.

147 de group and 314 to the tenofovir disoproxil fumarate group).

148 de group and 477 to the tenofovir disoproxil fumarate group.

149 pared with those in the tenofovir disoproxil fumarate group.

150 enz, emtricitabine, and tenofovir disoproxil fumarate group.

151 37 (12%) of 314 in the tenofovir disoproxil fumarate group; none of these were serious.

152 and 294 (94%) of 313 on tenofovir disoproxil fumarate had maintained less than 50 copies per mL HIV-1

153 (6%) patients receiving tenofovir disoproxil fumarate had serious adverse events, none of which was d

154 ir alafenamide or E/C/F/tenofovir disoproxil fumarate had virological success.

155 Fumarate has been shown to inhibit alpha-ketoglutarate-d

156 ral regimens containing tenofovir disoproxil fumarate have been associated with renal toxicity and re

157 e by muscle when compared with either PBS or fumarate, highlighting the effect of succinate on connec

158 ty than those receiving tenofovir disoproxil fumarate (hip -0.29% [95% CI -0.55 to -0.03] vs -2.16% [

159 at arises from pharmacological inhibition of fumarate hydratase (also known as fumarase).

160 in the tricarboxylic acid (TCA) cycle enzyme fumarate hydratase (FH) are associated with a highly mal

161 ng the tricarboxylic acid (TCA) cycle enzyme fumarate hydratase (FH) cause a hereditary cancer syndro

162 (MED12) mutations, biallelic inactivation of fumarate hydratase (FH), and collagen, type IV, alpha 5

163 Expression of fumarate hydratase (FH), which regulates urine fumarate

164 r survival and mutation of the gene encoding fumarate hydratase (FH).

165 In this study, we investigated the role of fumarate hydratase (Fh1), a key component of the mitocho

166 These results imply that loss of fumarate hydratase and fumarate accumulation contribute

167 Here we show that loss of fumarate hydratase and the subsequent accumulation of fu

168 a photoaffinity labeling strategy identified fumarate hydratase as the principal pharmacological targ

169 tions of the tricarboxylic acid cycle enzyme fumarate hydratase cause hereditary leiomyomatosis and r

170 Loss of fumarate hydratase is associated with suppression of miR

171 sociations, including a missense mutation in fumarate hydratase that controls variation in the mitoch

172 Fumarate hydratase, an essential enzyme in the tricarbox

173 zyme activity changes caused by mutations in fumarate hydratase, which underlie the familial cancer p

174 mall molecule metabolite that accumulates in fumarate hydratase-deficient cells, plays a key role in

175 Fumarate hydratase-deficient renal cancers are highly ag

176 ion contribute to the aggressive features of fumarate hydratase-deficient tumours.

177 imolar levels in succinate dehydrogenase and fumarate hydratase-mutant tumors, were identified as pot

178 anges are recapitulated by the incubation of fumarate hydratase-proficient cells with cell-permeable

179 knowledge, of the Mycobacterium tuberculosis fumarate hydratase.

180 Fumarate hydratases (FHs) are essential metabolic enzyme

181 oluene, enzymes conjugate these molecules to fumarate in a radical-catalyzed, C-C bond-forming reacti

182 We reveal channelling of citrate and fumarate in isolated potato mitochondria by isotope dilu

183 with an impaired accumulation of malate and fumarate in leaves.

184 ivirine, emtricitabine, tenofovir disoproxil fumarate in maintaining viral suppression and was well t

185 hydratase and the subsequent accumulation of fumarate in mouse and human cells elicits an epithelial-

186 ty of BMS-986001 versus tenofovir disoproxil fumarate in treatment-naive patients with HIV-1.

187 fective fortificant, was replaced by ferrous fumarate in wheat flour in 2002, and ferrous bisglycinat

188 oral emtricitabine plus tenofovir disoproxil fumarate in women.

189 Simultaneously, fumarate increases ferritin gene transcription by activa

190 Compared with tenofovir disoproxil fumarate, individuals in the BMS-986001 groups showed a

191 We demonstrate that fumarate inhibits Tet-mediated demethylation of a regula

192 tat, emtricitabine, and tenofovir disoproxil fumarate (integrase inhibitor regimen) or ritonavir-boos

193 Thus Osm1/fumarate is a new electron acceptor couple in the mitoch

194 Emtricitabine with tenofovir disoproxil fumarate is a standard-of-care nucleoside reverse transc

195 However, tenofovir disoproxil fumarate is associated with renal and bone toxic effects

196 with emtricitabine and tenofovir disoproxil fumarate is highly effective against acquisition of HIV

197 Fumarate is therefore a key link connecting metabolic pa

198 oral emtricitabine and tenofovir disoproxil fumarate is used to prevent the sexual acquisition of HI

199 that lacks the electrophilic double bond of fumarate, is unable to inhibit NFkappaB activity.

200 cumulation of the MDH substrate, malate, and fumarate, its immediate precursor in the Krebs cycle, in

201 Crystallographic analyses with succinate, fumarate, L-malate, oxaloacetate, pyruvate and D- and L-

202 pporting the hypothesis that accumulation of fumarate leads to activation of the oncogenic transcript

203 H, caused by the loss of FH, or by exogenous fumarate, leads to persistent oxidative stress and cellu

204 lacking mitochondrial Fh1 (which had normal fumarate levels but defective maximal mitochondrial resp

205 of extramitochondrial Fh1 (which normalized fumarate levels but not maximal mitochondrial respiratio

206 s to DKD pathogenesis, and measuring urinary fumarate levels may have application for monitoring rena

207 inary metabolites were increased in DKD, but fumarate levels were uniquely reduced by the NOX1/NOX4 i

208 xes II and III and increase matrix succinate/fumarate levels, we hypothesize that by allowing dicarbo

209 rough targeting of renal FH, which increases fumarate levels.

210 e metabolites including alpha-KG, succinate, fumarate, malate, and citrate were observed in TGF-beta1

211 rate, isocitrate, 2-oxoglutarate, succinate, fumarate, malate, and oxaloacetate) were tested for thei

212 Thus, we identify novel roles for fumarate metabolism in HSC maintenance and hematopoietic

213 tricarboxylic acid (TCA) cycle and cytosolic fumarate metabolism, in normal and leukemic hematopoiesi

214 issue is predominantly exposed to monomethyl fumarate (MMF), the bioactive metabolite of DMF, which c

215 g, and 66 to 400 mg) or tenofovir disoproxil fumarate (n=101).

216 alafenamide (n=333) or tenofovir disoproxil fumarate (n=330).

217 ion with 60 mg of elemental iron (as ferrous fumarate, n = 237 women) or placebo (n = 233) from rando

218 292 patients receiving tenofovir disoproxil fumarate), nasopharyngitis (56 [10%] vs 16 [5%]), and he

219 Toluene is held in place by fumarate on one face and tight packing by hydrophobic re

220 ice daily and 300 mg of tenofovir disoproxil fumarate once daily as a backbone.

221 ide and 141 assigned to tenofovir disoproxil fumarate; one patient assigned to tenofovir disoproxil f

222 tients receiving either tenofovir disoproxil fumarate or abacavir as part of their antiretroviral the

223 ween a pyrazinone and commercially available fumarate or maleate precursors is reported.

224 CI, 1.21-2.07; P = .001) but not quetiapine fumarate or olanzapine.

225 was observed after intratumoral injection of fumarate or PBS.

226 The combination of fumarate or succinate treatment with TET1 or TET3 silenc

227 ti-inflammatory mediators, that is, dimethyl fumarate, phosphodiesterase 4, and leukotriene B4 inhibi

228 daily oral combination tenofovir disoproxil fumarate plus emtricitabine, is an effective human immun

229 the third daily dose of tenofovir disoproxil fumarate plus emtricitabine.

230 aily oral emtricitabine-tenofovir disoproxil fumarate PrEP among 50 HIV-uninfected breastfeeding Afri

231 with emtricitabine and tenofovir disoproxil fumarate (protease inhibitor based regimen); regimens we

232 ovements in growth under increased glutamate:fumarate ratios.

233 is were remarkably similar under aerobic and fumarate-reducing conditions.

234 al photosynthetic systems utilizing either a fumarate reductase (FccA) for the solar-driven hydrogena

235 cherichia coli through interactions with the fumarate reductase (Frd) electron transport complex.

236 e Escherichia coli Complex II homolog quinol:fumarate reductase (QFR, FrdABCD) catalyzes the intercon

237 under microaerophilic conditions, the quinol:fumarate reductase can be utilized.

238 Here we show that the fumarate reductase Osm1, which facilitates electron tran

239 which contributes to proton shuttling during fumarate reduction, for detailed biophysical and structu

240 of 437 assigned to the tenofovir disoproxil fumarate regimen (difference -2.0%, 95.001% CI -5.9 to 1

241 dy drug and were on the tenofovir disoproxil fumarate regimen before screening were included in prima

242 f 99 patients receiving tenofovir disoproxil fumarate, respectively.

243 c1) was incubated under sulfate reducing and fumarate respiration conditions (SR and FR, respectively

244 6 years of exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazanavir, or ritonavir-boo

245 cumulative exposure to tenofovir disoproxil fumarate, ritonavir-boosted atazanavir, ritonavir-booste

246 rize, and evaluate 3D-printed poly(propylene fumarate) scaffolds is proposed for vascularized enginee

247 In vitro, fumarate stimulated endoplasmic reticulum stress, matrix

248 Tenofovir alafenamide fumarate (TAF), a new prodrug of tenofovir and a potenti

249 rsons who had ever used tenofovir disoproxil fumarate (TDF) (1.40; 1.15-1.70) or who were currently o

250 o take a combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) or placebo before

251 ly receive some form of tenofovir disoproxil fumarate (TDF) as part of their HIV treatment regimen.

252 Tenofovir disoproxyl fumarate (TDF) disoproxyl fumarate (TDF) has in vitro ac

253 The approved tenofovir disoproxil fumarate (TDF) dose of 300 mg every 48 hours for adults

254 nofovir disoproxyl fumarate (TDF) disoproxyl fumarate (TDF) has in vitro activity against herpes simp

255 spite widespread use of tenofovir disoproxil fumarate (TDF) in pregnant and breastfeeding women, few

256 and safety of maternal tenofovir disoproxil fumarate (TDF) in reducing mother-to-infant hepatitis B

257 Tenofovir disoproxil fumarate (TDF) is an established nucleotide analogue in

258 Tenofovir disoproxil fumarate (TDF) is associated with proximal tubular dysfu

259 Tenofovir disoproxil fumarate (TDF) is commonly used in antiretroviral treatm

260 Exposure to tenofovir disoproxil fumarate (TDF) may cause renal toxicity.

261 Tenofovir disoproxil fumarate (TDF) plays a pivotal role in antiretroviral th

262 cal studies of systemic tenofovir disoproxil fumarate (TDF) PrEP revealed reduced efficacy in women c

263 pid or slow response to tenofovir disoproxil fumarate (TDF) treatment, have been examined to identify

264 s receiving LDV/SOF and tenofovir disoproxil fumarate (TDF) without a protease inhibitor (PI) (0.18 [

265 itabine (FTC), MVC plus tenofovir disoproxil fumarate (TDF), and TDF plus FTC.

266 mtricitabine (FTC), MVC-tenofovir disoproxil fumarate (TDF), and TDF-FTC (control).

267 %), despite high use of tenofovir disoproxil fumarate (TDF), emtricitabine, and lamivudine and potent

268 potential successor of tenofovir disoproxil fumarate (TDF), has been approved in the United States a

269 ily treatment with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtricitabine (TDF-FTC),

270 a novel gel containing tenofovir disoproxil fumarate (TDF), the tenofovir prodrug, but not with the

271 red maraviroc (MVC)- to tenofovir disoproxil fumarate (TDF)-containing ART.

272 nd endocrine changes in tenofovir disoproxil fumarate (TDF)-related bone toxicity.

273 y approved formulation, tenofovir disoproxil fumarate (TDF).

274 ral emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF).

275 HSV-2 infection to oral tenofovir disoproxil fumarate (TDF)/placebo vaginal gel, oral placebo/tenofov

276 ns by 90% compared with tenofovir disoproxil fumarate, thereby decreasing bone and renal risks.

277 concentrations than does tenofovir disproxil fumarate, thereby minimising bone and renal risks.

278 ly at a lower dose than tenofovir disoproxil fumarate, thereby reducing systemic exposure.

279 from emtricitabine with tenofovir disoproxil fumarate to emtricitabine with tenofovir alafenamide, hi

280 (FccA) for the solar-driven hydrogenation of fumarate to succinate or a hydrogenase (H2ase) for reduc

281 m1, which facilitates electron transfer from fumarate to succinate, fills this gap as a new electron

282 iates anaerobic toluene metabolism by adding fumarate to the methyl group of toluene to yield (R)-ben

283 onsider PML in the differential diagnosis of fumarate-treated patients presenting with brain lesions

284 Clemastine fumarate treatment was associated with fatigue, but no s

285 ry efficacy endpoint was met with clemastine fumarate treatment, which reduced the latency delay by 1

286 endent of emtricitabine/tenofovir disoproxil fumarate use.

287 eimines and electron-poor olefins, to detect fumarate via fluorescent pyrazoline cycloadduct formatio

288 men from one containing tenofovir disoproxil fumarate was non-inferior for maintenance of viral suppr

289 enz, emtricitabine, and tenofovir disoproxil fumarate was non-inferior in maintaining viral suppressi

290 he material into 3D printable poly(propylene fumarate) was utilized to produce thin films and scaffol

291 redominantly containing tenofovir disoproxil fumarate) were also more likely to experience eGFR decli

292 ced by fingolimod, alemtuzumab, and dimethyl fumarate, whereas natalizumab disproportionally increase

293 e with 200 mg or 300 mg tenofovir disoproxil fumarate, while remaining on the same third agent for 96

294 ) of patients receiving tenofovir disoproxil fumarate who had HBV DNA less than 29 IU/mL (adjusted di

295 s patients treated with fumaric acid esters (fumarates), who had developed severe and long-standing l

296 r alafenamide or 300 mg tenofovir disoproxil fumarate with matching placebo.

297 oproxil fumarate (E/C/F/tenofovir disoproxil fumarate) with matching placebo.

298 s non-inferior to E/C/F/tenofovir disoproxil fumarate, with 800 (92%) of 866 patients in the tenofovi

299 e was as efficacious as tenofovir disoproxil fumarate, with reduced bone and renal toxic effects.

300 bolites, including Glc-6-P, Fru-6-P, malate, fumarate, Xyl, and ribose.